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Abstract 
Introduction: Chagas disease (CD) remains a public health concern in several Latin American countries. At global level, Bolivia has the highest 
CD burden and the Chaco region, in the southeast of the country, is the most affected area. We report the results of four serosurveys for 
Trypanosoma cruzi antibodies, carried out approximately ten years apart from each other, during the lapse 1987-2013, in different localities of 
the Bolivian Chaco. 
Methodology: Four cross-sectional surveys were conducted in various localities, mostly rural, of the Bolivian Chaco, during the period 1987-
2013. 
Results: Although a reliable analysis of CD epidemiological trend is challenging, a partial reduction of anti-T. cruzi seroprevalence over the 
past four decades in the Bolivian Chaco may be assumed. In particular, in 1987 the exposure to T. cruzi in rural setting was universal since the 
first years of life, while it resulted gradually lower and age-dependent thereafter. Moreover, T. cruzi seroprevalence among women of 
reproductive age (15-45 years) has been persistently high in rural areas. 
Conclusions: T. cruzi transmission is still active and CD remains a concern throughout the Bolivian Chaco. More efforts are needed in order to 
achieve a sustainable interruption of vector-borne CD transmission in this area. 
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Introduction 
Chagas disease (CD) or American trypanosomiasis, 
caused by the infection with the protozoan parasite 
Trypanosoma cruzi, is a public health concern in 
several Latin American countries. An estimated 6-7 
million people worldwide are infected by T. cruzi, and 
the most part remains unsuspected (it is named "the 
invisible disease"), undiagnosed or untreated [1]. 
Thanks to regional intergovernmental control 
programs, launched during the 1990s, e.g. the Southern 
Cone Initiative (1991), the Andean Pact Initiative, and 
the Central America Initiative (1997), vector-borne 
transmission due the main vector, Triatoma infestans 
(Reduviidae, Triatominae), has been interrupted in 
Uruguay, Chile, Brazil, Eastern Paraguay, and few 
provinces in Argentina [2]. By contrast, Bolivia has still 
the highest prevalence over the planet (6.1%), with an 
estimated 607,186 prevalent infections and an endemic 
area covering 60% of the country [3,4]. For this reason, 
Bolivian Health Authorities declared CD prevention 
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and control a national priority in Law 3374 dated March 
23, 2006 [5]. Control campaigns are promoted and 
managed by the National Program for Chagas Disease 
Control (NPCDC), with the main goal of reducing the 
proportion of infested houses to less than 3%. A 
considerable reduction was achieved in the last decades 
at national level, from an estimated 47.7% infestation 
rate (IR) in 1999 to 1.9% in 2016 [6]. However, control 
interventions obtained a limited success in the Bolivian 
Chaco, southeast of the Plurinational State of Bolivia, 
where the risk for T. infestans transmission continues to 
be high, and the house IR is still above 3% in the great 
part of the municipalities of the three Departments 
(Santa Cruz, Chuquisaca, and Tarija) [2,6].  
Among the research activities, realized since the 
late 1980s within the longstanding collaboration 
between the Infectious and Tropical Diseases Unit, 
University of Florence, Italy and the Bolivian Ministry 
of Health, four seroprevalence studies for T. cruzi 
antibodies have been carried out, in different rural and 
urban/semi-urban localities of the Bolivian Chaco. In 
this paper, we report the results of those T. cruzi 
surveys, conducted approximately ten years apart from 
each other during the lapse 1987-2013, in order to set 
out CD prevalence trend and to strengthen the 
awareness on the current CD burden in the extremely 
affected Bolivian Chaco region.  
 
Methodology 
Study area 
The Bolivian Chaco region is a semi-arid, 
homogeneous ecological zone, situated between the 
latitudes 17°59’ - 22°21’ South and the longitudes 
64°31’ - 58°51’ West, and is approximately 127 755 
km² in size. The region is sparsely-populated and 
consists of three Departments and five provinces 
(Cordillera, Luis Calvo, Hernando Siles, Gran Chaco, 
and O’Connor) (Figure 1). The inhabitants live in few 
small urban centres, and, for the most part, in rural 
communities, where households are poor dwellings, 
with walls of sticks, straw and clay and thatched roofs. 
People are mainly of the Guaraní ethnic group. Local 
economy is based on agriculture and animal farming 
[7]. 
 
Study populations 
We carried out four cross-sectional surveys 
throughout the territories of the Bolivian Chaco region, 
in 1987, 1997, 2006, and 2013, respectively. In all 
cases, prevalence of anti-T. cruzi antibodies was 
obtained as part of broader epidemiological surveys in 
human population of the Chaco region.  
Each study was firstly explained during a 
preparatory meeting, involving local health care 
providers and community leaders. With their 
collaboration, the invitation to participate, directed to 
all individuals of the communities, was disseminated 
during public meetings. Therefore, the surveyed 
populations consisted of healthy volunteers, 
consecutively enrolled among those who consented to 
participate (with the exception of the studies carried out 
in Camiri and Boyuibe in 1987, which included a 
number of hospitalized patients). 
In 1987, the study population included individuals 
from three different settings of the Cordillera Province 
(Department of Santa Cruz): Camiri, (a little urban 
centre of approximately 30,000 inhabitants); Boyuibe, 
(a semi-urban municipality of about 2,500 inhabitants), 
and Javillo (an extremely isolated rural community of 
about 110 people). In Camiri and Boyuibe, the study 
population consisted of primary and secondary school 
children and in- and out-patients of the local hospitals 
(178 people in Camiri, 184 in Boyuibe, age range 1-75 
Figure 1. Map of the Bolivian Chaco (grey area). 
The area of the Bolivian Chaco lies in the south-east of the country, and 
includes 3 Departments (numbers on the map: Santa Cruz = 1; 
Chuquisaca = 2; Tarija = 3) and 5 Provinces (letters on the map: 
Cordillera = A;, Hernando Siles = B; Luis Calvo = C; Gran Chaco = D; 
O’Connor = E). 
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years), whereas in Javillo almost the entire population 
was enrolled (84 people, age range 4-70 years). 
In the following studies, we surveyed only 
populations living in rural areas. In 1997, the survey 
concerned rural communities in the neighborhood of 
Camiri and Villa Montes (Gran Chaco Province, 
Department of Tarija), each having approximately 
3,300 inhabitants. The sample size was adequate for an 
expected anti-T. cruzi antibodies prevalence of 80%, 
with a worst acceptable error of 5% and a confidence 
interval of 95%. The study populations consisted of 238 
individuals from Camiri and 250 individuals from Villa 
Montes (age range 1-85 years).  
In 2006, we surveyed the rural community of 
Bartolo (Hernando Siles Province, Department of 
Chuquisaca). Blood samples were taken from ≈80% of 
the community populations (161 persons, age range 1–
77 years). 
In 2013, 90 individuals (≈45% of the community 
populations; age range 1–83 years) were enrolled in the 
rural community of Bartolo, and 126 people (≈25% of 
the community populations, age range 1–83 years) were 
enrolled in Ivamirapinta (Cordillera Province, 
Department of Santa Cruz). 
 
Serologic assays 
For all subjects, demographic data (sex, age) were 
recorded, and a sample of 5-10 ml venous blood was 
collected, stored at -20°C in Bolivia, then transported to 
Italy and stored at -70°C until tested. Serological tests 
were performed by using an indirect hemagglutination 
assay (IHA) in 1987 (Cellognost-Chagas, Behring 
Institute, Germany) and 1997 (Chagas Polychaco kit, 
Lemos Laboratories, Argentina), fixing the cutoff at 1:8 
dilution, according to WHO recommendations [8]. In 
the surveys conducted in 2006 and 2013, two 
conventional tests based on different principles and 
detecting different antigens were used. In the case of 
ambiguous or discordant results, a third test has been 
used. In details, in 2006 samples were tested by a high-
performing rapid diagnostic test (RDT) (Chagas Quick 
test, Cypress Diagnostic, Belgium), a based on a 
recombinant antigen, composed of nine different 
epitopes and by an immunoenzymatic assay (EIA) 
(Chagas Trypanosoma cruzi IgG, DRG Diagnostic, 
Germany), which used as antigens the Trypanosoma 
cruzi lysate.  
In 2013, we used two enzyme-linked 
immunosorbent assays (ELISA) (NovaLisa Chagas 
Trypanosoma cruzi IgG, NovaTec Immundiagnostica 
GmbH, Germany; ORTHO T. cruzi ELISA Test 
System, Ortho-Clinical Diagnostics, Inc) based on T. 
cruzi recombinant and whole cell lysate antigens, 
respectively. A third test (BioELISA Chagas, Biokit 
S.A, Spain) based on recombinant antigens, was used to 
disclose discordance. Assays were performed and cut-
off determined according to the respective 
manufacturer’s instructions. Negative and positive 
controls provided in the kit were included in each 
serological run. 
 
Ethics 
The studies were programmed and conducted in 
agreement with the Ministry of Health of the 
Plurinational State of Bolivia (within the Convenio 
Ministerio de Salud y Deportes, Estado Plurinacional de 
Bolivia/Cátedra de Enfermedades Infecciosas, 
Universidad de Florencia, Italia), and with the support 
of the Guaraní political organization (Asamblea del 
Pueblo Guaraní). The study was approved by a local 
Ethics Committee (Colegio Médico de Santa Cruz, 
TDEM CITE No. 028/2017). 
 
Statistical analysis 
Statistical analysis of data was performed with 
STATA 11.0 (StataCorp, College Statio, TX, USA). 
Frequencies and percentages with 95% confidence 
intervals (CI) for categorical variables, medians, and 
interquartile ranges (IQR) for continuous variables 
were calculated. Chi-square test and logistic regression 
were used to investigate the association of positive tests 
with sex and age, respectively. Results were considered 
significant when the p-value was ≤ 0.05. 
 
Results 
Demographic details and age-stratified T. cruzi 
seroreactivity of the populations studied in our cross-
sectional surveys are shown in detail in Table 1. In the 
Cordillera Province (Department of Santa Cruz), in 
1987 we found a seroprevalence for T. cruzi of 73% 
(129/178) and 64% (117/184) in urban and semi-urban 
areas, respectively. At the same time, a significantly 
higher rate was found in the rural community of Javillo, 
where 98% (82/84) of the inhabitants presented anti-T. 
cruzi antibodies (p < 0.001, age-stratified Cochran-
Mantel-Haenszel test). In the subsequent decades, we 
conducted two further surveys in similar rural settings 
of the Cordillera Province. In 1997, seroprevalence was 
81% (193/238) in some rural communities near Camiri, 
while in 2013, we found 60% of positivity (76/126) in 
Ivamirapinta (municipality of Gutierrez). 
As far as the Chaco territories belonging to the 
Department of Chuquisaca are concerned, in the two 
consecutive surveys we conducted in the rural 
Spinicci et al. – Anti-T. cruzi antibodies in Bolivia (1987-2013)     J Infect Dev Ctries 2020; 14(2):199-206. 
202 
community of Bartolo (municipality of Monteagudo, 
Hernando Siles Province) in 2006 and 2013, a not 
significant decline in T. cruzi seroprevalence was 
observed (70% and 63%, respectively, p = 0.106). 
Similarly, seropositivity rate among 1-10 year-old 
children showed a slight, not significant decline from 
2006 to 2013 (25% and 20%, respectively, p = 0.666). 
In the Department of Tarija, we found a 
seroprevalence of 74% (184/250) in rural communities 
around the city of Villa Montes (Gran Chaco Province) 
in 1997. 
In all the surveyed populations, distribution of CD 
did not differ by sex, while it increased according to age 
(in all cases excluding Javillo – 1987, where exposure 
resulted universal since the first years of life). 
Moreover, T. cruzi seroprevalence among women of 
reproductive age (15-45 years) has been persistently 
high in rural areas, ranging from 100% in 1987 to 74-
79% of the most recent determinations in 2013 (Table 
1).  
 
Discussion 
Relatively few studies reported data on CD 
epidemiology in the Bolivian Chaco, although it is 
acknowledged as one of the most affected areas in the 
planet. In Table 2, we report a summary of the main 
available studies concerning anti-T. cruzi antibodies 
seroprevalence in the human population of the Bolivian 
Chaco [9–13]. A detailed and accurate analysis of the 
epidemiological evolution is challenging, being 
hindered by several limitations. Above all, various 
serological techniques have been used in the different 
periods (IHA, EIA, ELISA, RDT), basically due to the 
sequential development and availability of newer 
assays along the years. However, as for the older IHA, 
whereas sensitivity widely varied from different 
manufacturers, specificity was considered very high 
(98-99%), suggesting that the high prevalence found in 
the first studies was not overestimated [14,15]. On the 
other hand, results from more recent studies are 
generally based on more than one serological test, being 
a definitive diagnosis of T. cruzi infection defined by at 
Table 1. Seroprevalence for IgG anti Trypanosoma cruzi in the human population of the surveyed localities in 1987, 1997, 2006, 2013. 
 Age Seroprevalence for IgG anti Trypanosoma cruzi 
 Median (range) Male Female 
1-5 
years 
6-10 
years 
11-20 
years 
21-40 
years 
> 40 
years 
Women 
of 
reproductive 
age 
(15-45 years) 
Overall 
prevalence 
(95%CI) 
1987  
Camiri1 17 (1-75) 24/30 80.0% 
105/148 
71.0% 
3/15 
20.0% 
10/12 
83.3% 
58/88 
66.0% 
44/49 
89.8% 
14/14 
100% 
75/102 
73.5% 
129/178 
72.5% 
(66.0-79.0) 
Boyuibe1 13 (4-75) 46/75 61.3% 
71/109 
65.1% 
1/3 
33.3% 
37/51 
72.5% 
66/108 
61.1% 
12/21 
57.1% 
1/1 
100% 
21/36 
58.3% 
117/184 
63.6% 
(56.6-70.5) 
Javillo1 16 (4-70) 35/36 97.2% 
47/48 
98.0% 
5/5 
100% 
21/23 
91.3% 
23/23 
100% 
21/21 
100% 
12/12 
100% 
22/22 
100% 
82/84 
97.6% 
(94.4-100) 
1997  
Camiri1 
(rural communities) 20 (2-80) 
84/104 
80.8% 
109/134 
81.3% 
14/24 
58.3% 
35/54 
64.8% 
29/43 
67.4% 
53/55 
96.4% 
62/62 
100% 
48/51 
94.1% 
193/238 
81.1% 
(76.1-86.1) 
Villa Montes2 
(rural communities) 
20.5 (1-
85) 
87/118 
73.7% 
97/132 
73.5% 
12/27 
44.4% 
32/51 
62.7% 
34/47 
72.3% 
51/64 
79.7% 
55/61 
90.2% 
39/47 
83.0% 
184/250 
73.6% 
(68.1-79.1) 
2006  
Bartolo3 24 (1-77) 65/92 70.7% 
47/69 
68.1% 
3/16 
18.8% 
7/24 
29.2% 
18/33 
54.5% 
38/39 
97.4% 
46/49 
93.9% 
21/22 
95.5% 
112/161 
69.6% 
(62.5-76.7) 
2013  
Ivamirapinta1 
 25 (2-75) 
28/57 
49.1 % 
48/69 
69.6% 
0/7 
0.0% 
1/19 
5.3% 
13/32 
40.6% 
26/30 
86.7% 
36/38 
94.7% 
26/33 
78.8% 
76/126 
60.3% 
(51.8-68.9) 
Bartolo3 30 (1-83) 31/49 63.2% 
26/41 
63.4% 
2/9 
22.2% 
2/11 
18.2% 
5/11 
45.5% 
22/30 
73.3% 
27/29 
93.1% 
14/19 
73.7% 
57/90 
63.3% 
(53.4-73.2) 
1Cordillera Province, Department of Santa Cruz; 2Gran Chaco Province, Department of Tarija; 3Hernando Siles Province, Department of Chuquisaca. 
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least two positive results, as recommended by the WHO 
[16]. Commercial ELISA used in our studies, have 
shown a pooled sensitivity of 99.3% (97.9%–99.9%) 
and a pooled specificity of 97.5% (88.5%–99.5%) in a 
meta-analysis [17]. Moreover, the surveys took place in 
different communities, and comprehensive information 
on entomological situation and insecticide-based 
interventions are sparse or not available for the great 
part of the surveyed communities. The Bolivian Chaco 
is a homogeneous ecological zone and the rural 
populations share the same living and health conditions. 
Here, the maintenance of active transmission is fostered 
by the reinvasion of the poor human dwellings by 
residual triatomine populations from areas not well 
treated in the domicile or in the peridomicile, or from 
neighboring untreated areas. This problem is enhanced 
by the recent emergence of foci of resistance to 
pyrethroid insecticides [10,18]. In the area of Gutierrez 
(Cordillera Province), systematic spray campaigns 
against domestic T. infestans, through blanket spraying 
Table 2. Available studies reporting anti-Trypanosoma cruzi antibodies seroprevalence in the human population of the Bolivian Chaco. 
References Year Setting Municipality Population 
Age 
median 
(range) 
anti-T. cruzi 
seroprevalence Test 
Santa Cruz Department (Cordillera Province) 
Romero, et al. 
[8] 1977 
Gutierrez - Ipitá 
(semi-urban area) Gutierrez 
General 
population NA (1-70) 70.6% (381/540) IHA 
This study 1987 
Camiri 
(urban area) Camiri 
School children 
& 
in- / out-
patients 
17 (1-75) 72.5% (129/178) IHA 
Boyuibe 
(Semi-urban area) Boyuibe 
School children 
& 
in- / out-
patients 
13 (4-75) 63.6% (117/184) IHA 
Javillo 
(rural community) Gutierrez 
General 
population 16 (4-70) 97.6% (82/84) IHA 
This study 1997 
Vicinity of Camiri 
(rural 
communities) 
Camiri General population 20 (2-80) 81.1% (193/238) IHA 
Samuels, et al. 
[9] 
2011-
12 
Eity health sector 
(rural 
communities) 
Gutierrez General population 
15 (IQR: 8-
33) 51.7% (799/1545) IHA, EIA, ELISA* 
Shah, et al. [10] 2011-12 
Vicinity of 
Gutierrez 
(rural 
communities) 
Gutierrez Children 9.5 (2-17) 39.5% (79/200) IHA, IFA, EIA* 
This study 2013 Ivamirapinta (rural community) Gutierrez 
General 
population 25 (2-75) 60.3% (76/126) ELISA (3 assays)* 
Chuquisaca Department (Hernando Siles Province) 
This study 2006 Bartolo (rural community) Monteagudo 
General 
population 24 (1-77) 69.6% (112/161) ICT, EIA, ELISA* 
This study 2013 Bartolo (rural community) Monteagudo 
General 
population 30 (1-83) 63.3% (57/90) ELISA (3 assays)* 
Tarija Department (Gran Chaco and O’Connor Province) 
This study 1997 
Vicinity of Villa 
Montes 
(rural 
communities) 
Villa Montes General population 20.5 (1-85) 73.6% (184/250) IHA 
Chippaux, et al. 
[11] 2007 
Vicinity of 
Caraparí 
(rural 
communities) 
Caraparí General population 25.4 (NA) 48.4% (482/995) ELISA 
Yun, et al. [12] 2002-06 
Vicinity of Entre 
Rios 
(rural 
communities) 
Entre Ríos Children < 15 years 19.4% (1475/7613) ELISA (2 test), IHA* 
IHA: indirect hemagglutination assay, IFA: immunofluorescent-antibody test, EIA: immunoenzymatic assay; ELISA: enzyme-linked immunosorbent assay. 
NA: not available; IQR: interquartile range; Data are presented in chronological order, after grouping by Department; *Final status was defined as positive if 
results were positive by at least two of the three tests and negative if results were positive by none or one of the assays. 
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with alphacypermethrin 20%, were conducted in 2000 
and 2003. Moreover, in early 2000, housing 
improvements such as whitewash, wall plastering 
and/or substitution of tin roofs for those of thatch, were 
provided within an intervention program by Caritas, a 
nongovernmental organization [10]. In the following 
years (2006-2013), periodical assessments for 
household vector IR and focal spraying of infested 
houses were performed in the municipalities of the 
Cordillera Province, as part of the NPCDC. Focal 
interventions achieved a partial, temporary control of 
the IR, which sharply fluctuated along the years. In the 
municipality of Gutierrez, household (vivienda) IR had 
a dramatic decline after the 2000-2003 systematic 
interventions (from 81.5% in 2000 to 0.8% in 2004), 
then rose to 44.8% in 2008, and decreased again to 10% 
in 2012. In Ivamirapinta, the most recent intervention 
was carried out few months before our survey in 2013, 
and detected a household IR of 16% (31/189 viviendas) 
(personal communication, R. Vargas, 2018). Given the 
limited efficacy of the traditional programs, based on 
indoor and outdoor residual insecticide spraying, 
alternative experimental strategies have been proposed. 
In 2006, a vector control intervention, based on 
microencapsulated organophosphate formulations, 
instead of the traditional suspension concentrate 
formulation applied with spraying pumps, showed 
promising results in the municipalities of Cuevo and 
Lagunillas (Cordillera Province, Santa Cruz 
Department) [19]. The study included an entomological 
evaluation of the house infestation by T. infestans 
before the intervention, which showed an overall 
infestation of either intra and/or peridomestic 
infestation of 30.5%. Furthermore, an ecosystem 
approach for the control of CD in the Bolivia Chaco, 
based on the identification of the ecological, biological 
and social determinants of CD transmission was 
proposed in rural villages of the Cordillera Province to 
reduce the risks of house infestation [20]. Knowledge, 
attitudes and practices on the vector, CD and its 
prevention were deficient. Living conditions, which 
encompass wall conditions and cleanliness of the room, 
and the presence of domestic animals in rooms, in 
particular poultry, resulted the main risk factor for 
house infestation. Education activities and an integrated 
vector control approach, based on simple and low cost 
interventions on the domicile environment were 
realized through community participation, leading to a 
significant decrease T. infestans densities in the 
domiciles. Recently, the presence of multiple animal 
reservoirs, including canine population, was confirmed 
as a further challenge for disease control and prevention 
strategies in this area [21]. 
In fact, whilst burdened by some limitations, 
available data confirmed that T. cruzi transmission is 
still active throughout this area, both via vectorial and 
vertical route, albeit a partial reduction over the past 40 
years may be assumed (Figure 2). This trend is 
especially accounted for by the youngest generations, 
reflecting a contained CD transmission in recent years, 
likely due to an improvement in housing conditions 
over time and the successful vector control programs. 
On the other hand, positivity rates in people >40 years 
old are still over 90%, reflecting the intense vector-
borne T. cruzi exposure over the past decades, which 
resulted in a chronic, lifelong infection (Figure 3). 
Subjects with chronic asymptomatic infection 
(indeterminate phase) had 30% to 40% of likelihood to 
Figure 2. Trypanosoma cruzi seroprevalence in the human 
population from urban, semi-urban and rural areas of the 
Bolivian Chaco, in the period 1987-2013. 
Checkered columns = urban/semi-urban area; full columns = rural area. 
Figure 3. Age-specific trends of T. cruzi seroreactivity rates, in 
the human population living in rural communities of the 
Bolivian Chaco, in the period 1987-2013. 
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develop the chronic phase complications, with a 
cardiac, digestive, neurological, or mixed involvement, 
decades after the initial infection [22]. Cardiac disease 
could lead to progressive heart failure and sudden 
death, which are the main causes of death in patients 
with chronic Chagas heart disease [23]. In 2011, a high 
prevalence of ECG abnormalities and substantial 
evidence of Chagas cardiomyopathy (55/398, 13.8%), 
including bundle branch and/or atrioventricular blocks 
and rhythm disturbances associated with impaired left 
ventricular end-diastolic dimensions or ejection 
fraction, were found in a population-based survey 
among T. cruzi infected inhabitants living in a rural area 
of the Bolivian Chaco [24]. As expected, the prevalence 
of any abnormality rose proportionally with the age. 
The authors called for improving the access to basic 
cardiac care, such as annual ECG, antiarrhythmics, 
pacemakers, which could have an immediate impact on 
CD morbidity and mortality. By merging these 
findings, and the CD prevalence reported in the few 
available studies, the Working Group on Chagas 
Disease in Bolivia and Peru estimated that between 
3,000 and 4,000 people in the Bolivian Chaco are in 
need of pacemakers [25].  
The screening of pregnant women and the early 
treatment of infected newborns are priorities for the 
Bolivian NPCDC started in 2004. The program was 
based on serological testing during pregnancy, follow-
up of children born from positive mothers until one year 
old, and treatment of positive children [26]. At national 
level, in 2016 the infection rate among pregnant women 
was 16.4%, and maternal transmission in Bolivia was 
estimated between 1.3% and 2.3% [6]. In the Bolivian 
Chaco both these rates are likely higher than the average 
of the country, especially in rural areas, where maternal 
seroprevalence stands at 60-70% and congenital 
transmission rate at 4-6%. Maternal risk factors for 
vertical transmission included higher circulating 
parasite loads, alterations in maternal immune response, 
younger age and twin births [27,28]. Of note, sustained 
domestic vector exposure, occurring in women living in 
infested houses, has been associated with decreased 
parasitemia and lower congenital transmission risk 
[28]. Furthermore, available data are still too scarce to 
elucidate whether maternal T. cruzi infection has an 
impact on fetal outcome. In the absence of effective 
vertical transmission, chronic maternal T. cruzi 
infection did not show effect on gestation outcome and 
fetal development [29]. However, early detection of 
congenital infection remains crucial. Benznidazole 
showed good efficacy and tolerance in the treatment of 
congenital Chagas disease [30]. In addition, the impact 
of treatment of women of childbearing age in 
preventing the vertical CD transmission have been 
recently highlighted [31]. 
 
Conclusion 
Although positive steps have been taken in the last 
decades, CD remains a major public health concern 
throughout the Bolivian Chaco. Here, as well as in the 
neighbouring areas of Northwest Argentina, and 
Paraguay (known as Gran Chaco region in its entirety), 
an effective vector control is still challenging. The 
reduction to 0 of the high risk municipalities and the 
strengthening of the Program (Atención Integral de la 
Enfermedad de Chagas) are a specific target of the 
Developing Sectorial Plan 2016-2020 [6]. Long-term 
repeated insecticide-based campaigns need to be 
integrated with housing improvements and surveillance 
system in order to achieve a sustainable interruption of 
vector-borne CD transmission in this area.  
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